Key facts
- This page summarizes James Treco's Form 4 filing for Tonix Pharmaceuticals Holding Corp. (TNXP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2025, 16:15.
James Treco - 20 Aug 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)
- Reporting relationship
- Director
- Issuer ticker
- TNXP
- Reported as of
- 20 Aug 2025
- Net transaction value
- +$9,000
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2025, 16:15:15 UTC
- Prior SEC filing
- 15 May 2025
- Next SEC filing
- 14 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jessica Morris, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Treco filed Form 4 for Tonix Pharmaceuticals Holding Corp. (TNXP) on 20 Aug 2025.
Change
- Previous filing in this sequence was filed on 15 May 2025.
- Current net transaction value: +$9,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001766070
Primary reporting owner
Treco James
- Relationship
- Director
- Address
- C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101, CHATHAM
- Signature
- /s/ Jessica Morris, Attorney-in-Fact
- Signature date
- 20 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TNXP
transaction
Common Stock, par value $0.001
Purchase
- Transaction value
- $9,000
- Shares
- +250
- Change %
- Price
- $36.00
- Shares after
- 250
- Date
- 20 Aug 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.